The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis.

Tapper, Elliot B; Hughes, Michael S; Buti, Maria; Dufour, Jean-François; Flamm, Steve; Firdoos, Saima; Curry, Michael P; Afdhal, Nezam H (2017). The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation, 101(5), pp. 987-995. Lippincott Williams & Wilkins 10.1097/TP.0000000000001400

[img]
Preview
Text
The optimal timing of hepatitis C therapy.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (2MB) | Preview

BACKGROUND Ledipasvir/sofosbuvir (LDV/SOF) has demonstrated high efficacy, safety and tolerability in HCV-infected patients. There is limited data, however, regarding the optimal timing of therapy in the context of possible liver transplantation (LT). METHODS We compared the cost-effectiveness of 12 weeks of HCV therapy before or after LT or nontreatment using a decision analytical microsimulation state-transition model for a simulated cohort of 10 000 patients with HCV Genotype 1 or 4 with Child B or C cirrhosis. All model parameters regarding the efficacy of therapy, adverse events and the effect of therapy on changes in model for endstage liver disease (MELD) scores were derived from the SOLAR-1 and 2 trials. The simulations were repeated with 10 000 samples from the parameter distributions. The primary outcome was cost (2014 US dollars) per quality adjusted life year (QALY). RESULTS Treatment before LT yielded more QALY for less money than treatment after LT or nontreatment. Treatment before LT was cost-effective in 100% of samples at a willingness-to-pay threshold of $100 000 in the base-case and when the analysis was restricted to Child B alone, Child C, or MELD > 15. Treatment before transplant was not cost-effective when MELD was 6-10. In sensitivity analyses, the MELD after which treatment before transplant was cost-effective was 13 and the maximum cost of LDV/SOF therapy at which treatment before LT is cost-effective is $177,381. CONCLUSION From a societal perspective, HCV therapy using LDV/SOF with ribavirin prior to LT is the most cost-effective strategy for patients with decompensated cirrhosis and MELD > 13.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Dufour, Jean-François

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0041-1337

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Lilian Karin Smith-Wirth

Date Deposited:

15 May 2017 09:58

Last Modified:

15 May 2017 09:58

Publisher DOI:

10.1097/TP.0000000000001400

PubMed ID:

27495755

BORIS DOI:

10.7892/boris.93546

URI:

https://boris.unibe.ch/id/eprint/93546

Actions (login required)

Edit item Edit item
Provide Feedback